Hyperbaric oxygen therapy involves breathing pure oxygen inside a chamber pressurized above sea level, which forces far more oxygen into the blood plasma than normal breathing can. For a small set of conditions this is established medicine with a clear mechanism. The FDA has cleared hyperbaric chambers for thirteen specific uses, among them carbon monoxide poisoning, decompression sickness, air embolism and certain severe burns and non-healing wounds.

Walk into a wellness clinic offering chamber sessions and the advertised list is considerably longer. The FDA's own consumer guidance names cancer, autism, Alzheimer's, multiple sclerosis, depression, heart disease, migraine and stroke among conditions for which chambers are marketed without the safety and effectiveness having been established. The agency says it has received complaints about such claims. This is a useful case to understand carefully, because the therapy is neither fringe nor harmless, and the distinction between the two lists is where all the information sits.

From the Lab to the Ledger

Hemoglobin in red cells is already close to fully saturated with oxygen under ordinary conditions, so breathing more oxygen at normal pressure adds little. Pressure changes that. Under two or three atmospheres, oxygen dissolves directly into blood plasma in quantities that can supply tissue even where red cells cannot reach, which is exactly the problem in a gas embolism, in crush injury, and in tissue damaged by radiation therapy years earlier.

That mechanism also explains the shape of the evidence. Where the clinical problem is an acute, local oxygen deficit with a defined endpoint, hyperbaric oxygen has a plausible role and trial support. Carbon monoxide poisoning is the clearest case: carbon monoxide binds hemoglobin far more tightly than oxygen does, and raising dissolved plasma oxygen displaces it faster. Diabetic foot ulcers and radiation-damaged tissue are harder cases where the evidence is more mixed and the indication depends on the specifics.

The same logic explains why the protocol matters as much as the device. Pressure and session length were set by the trials behind each indication, and a clinic running shorter sessions at lower pressure is not delivering a scaled-down version of the studied treatment so much as an untested one.

Where the proposed benefit is general, the mechanism stops doing useful work. Claims about cognition, longevity, athletic recovery and chronic fatigue typically appeal to improved oxygen delivery or reduced inflammation in the abstract, without a tissue that is demonstrably oxygen-starved or an endpoint that can be measured. That is the signature of a treatment being applied to a problem it was not designed for.

Bio-Pipeline Ledger

The thirteen FDA-cleared indications: validated and reimbursed, including carbon monoxide poisoning, decompression sickness, air or gas embolism, severe anemia, certain burns and selected non-healing wounds. This is the list that has evidence behind it.

Diabetic foot ulcers and radiation tissue injury: within the cleared set but with evidence that varies by patient and wound, and with specialist selection criteria. Available and clinically appropriate in defined cases rather than broadly.

Hyperbaric oxygen for neurological and cognitive conditions: studied in small trials including post-concussion syndrome and post-stroke recovery, with results that remain inconclusive. Not cleared, and not validated for broad use.

Hyperbaric oxygen marketed for longevity, anti-aging or general wellness: no clearance and no controlled evidence of benefit on any aging endpoint. This is marketing rather than medicine.

Mild home or portable soft chambers: sold directly to consumers at lower pressures than clinical systems, outside the clearances that apply to medical chambers. Not validated, and carrying their own fire and pressure risks.

The Clinical Reality Check

The most important thing to say plainly is that this is not a harmless therapy being oversold. The FDA names ear and sinus pain and joint pain as common effects, and paralysis and air embolism among the serious ones. A chamber is an oxygen-enriched environment, which makes fire a real and documented hazard. There have been injuries and deaths in non-medical settings.

The agency also names a risk that gets less attention and probably matters more: a patient who pursues an unproven chamber course for a serious condition may delay or forgo a treatment that works. That cost is invisible on any clinic's consent form.

The practical questions are short. Is the condition on the cleared list, and if not, what controlled evidence exists for it. Is the chamber a medical-grade system operated by trained staff with a physician involved. Is anyone framing this as a complement to standard treatment or as a replacement for it, because the second answer is a reason to leave.

None of this is an argument against hyperbaric medicine, which is genuinely life-saving in the settings it was developed for. It is an argument for noticing when a specific, mechanistically grounded treatment is lifted out of its context and sold as a general one. That pattern repeats across this field, and the thirteen-item list is an unusually clear place to see it.